中国地方病学杂志
中國地方病學雜誌
중국지방병학잡지
CHINESE JOURNAL OF ENDEMIOLOGY
2013年
1期
85-87
,共3页
刘学慧%陈慧民%刘庆斌%王革%刘晓波%田淑彩%璋显坤%英殿双%姜志立
劉學慧%陳慧民%劉慶斌%王革%劉曉波%田淑綵%璋顯坤%英殿雙%薑誌立
류학혜%진혜민%류경빈%왕혁%류효파%전숙채%장현곤%영전쌍%강지립
99m锝美罗酸盐%硫酸软骨素%治疗%大骨节病
99m锝美囉痠鹽%硫痠軟骨素%治療%大骨節病
99m득미라산염%류산연골소%치료%대골절병
Technetium Tc 99 m Medronate%Chondroitin sulfate%Treatment%Kashin-Beck disease
目的 通过锝[99TC]亚甲基二磷酸盐(云克)与硫酸软骨素联合用药观察药物疗效,为临床治疗成人大骨节病提供科学数据.方法 按照《大骨节病诊断标准》(GB 16003-1995),在呼伦贝尔市大骨节病病区选择79例大骨节病患者,分为治疗组与对照组.治疗组44人,给予静脉注射云克和口服硫酸软骨素;对照组35人,仅静脉注射云克.3个月后观察效果[以治疗前后疼痛、功能改善情况、骨关节炎指数(WOMAC)变化情况进行判定].结果 治疗组和对照组经过3个月治疗后,疼痛症状及关节功能恢复显效率分别为81.82％(36/44)和60.00％(21/35);有效分别为15.91％(7/44)和34.29％(12/35)；无效分别为2.72％ (1/44)和5.71％(2/35)；总有效率分别为97.73％(43/44)和94.29％(33/35).治疗组和对照组患者治疗前后握力、15 m步行时间、血钙、WOMAC指数比较,差异均有统计学意义(治疗组t=3.37、7.99、8.73、16.19,P均＜0.05；对照组t=6.21、9.46、5.49、8.73,P均＜0.05).两组之间疗效比较差异无统计学意义(x2=1.06,P＞ 0.05).结论 云克与硫酸软骨素联合或单独用药,都是目前治疗大骨节病理想、疗效可靠的药物治疗方法,值得临床推广应用.
目的 通過锝[99TC]亞甲基二燐痠鹽(雲剋)與硫痠軟骨素聯閤用藥觀察藥物療效,為臨床治療成人大骨節病提供科學數據.方法 按照《大骨節病診斷標準》(GB 16003-1995),在呼倫貝爾市大骨節病病區選擇79例大骨節病患者,分為治療組與對照組.治療組44人,給予靜脈註射雲剋和口服硫痠軟骨素;對照組35人,僅靜脈註射雲剋.3箇月後觀察效果[以治療前後疼痛、功能改善情況、骨關節炎指數(WOMAC)變化情況進行判定].結果 治療組和對照組經過3箇月治療後,疼痛癥狀及關節功能恢複顯效率分彆為81.82％(36/44)和60.00％(21/35);有效分彆為15.91％(7/44)和34.29％(12/35)；無效分彆為2.72％ (1/44)和5.71％(2/35)；總有效率分彆為97.73％(43/44)和94.29％(33/35).治療組和對照組患者治療前後握力、15 m步行時間、血鈣、WOMAC指數比較,差異均有統計學意義(治療組t=3.37、7.99、8.73、16.19,P均＜0.05；對照組t=6.21、9.46、5.49、8.73,P均＜0.05).兩組之間療效比較差異無統計學意義(x2=1.06,P＞ 0.05).結論 雲剋與硫痠軟骨素聯閤或單獨用藥,都是目前治療大骨節病理想、療效可靠的藥物治療方法,值得臨床推廣應用.
목적 통과득[99TC]아갑기이린산염(운극)여류산연골소연합용약관찰약물료효,위림상치료성인대골절병제공과학수거.방법 안조《대골절병진단표준》(GB 16003-1995),재호륜패이시대골절병병구선택79례대골절병환자,분위치료조여대조조.치료조44인,급여정맥주사운극화구복류산연골소;대조조35인,부정맥주사운극.3개월후관찰효과[이치료전후동통、공능개선정황、골관절염지수(WOMAC)변화정황진행판정].결과 치료조화대조조경과3개월치료후,동통증상급관절공능회복현효솔분별위81.82％(36/44)화60.00％(21/35);유효분별위15.91％(7/44)화34.29％(12/35)；무효분별위2.72％ (1/44)화5.71％(2/35)；총유효솔분별위97.73％(43/44)화94.29％(33/35).치료조화대조조환자치료전후악력、15 m보행시간、혈개、WOMAC지수비교,차이균유통계학의의(치료조t=3.37、7.99、8.73、16.19,P균＜0.05；대조조t=6.21、9.46、5.49、8.73,P균＜0.05).량조지간료효비교차이무통계학의의(x2=1.06,P＞ 0.05).결론 운극여류산연골소연합혹단독용약,도시목전치료대골절병이상、료효가고적약물치료방법,치득림상추엄응용.
Objective To observe the clinical therapeutic efficiency of technetium (yunke) combined with chondroitin sulfate,and to provide a scientific data for clinical treatment of adults patients with Kashin-Beck disease(KBD).Methods In accordance with "Kashin-Beck Disease Diagnostic Criteria"(GB 16003-1995),79 cases of KBD patients in Hulunbuir city were selected and divided into treatment group and control group.Treatment group(n =44) were given intravenous yunke and oral chondroitin sulfate,and control group(n =35)were given intravenous yunke only.The effect was observed after 3 months by womac index(judged by pain,function improvement and WOMAC index chanse before and after the treatment).Results The pain and joint function had improved after the treatment in two groups.The significant effective rate was 81.82％ (36/44) and 60.00％(21/35),respectively; effective rate was 15.91％(7/44) and 34.29％(12/35),respectively; invalid rate was 2.72％ (1/44) and 5.71％(2/35),respectively; total effective rate was 97.73％(43/44) and 94.29％(33/35),respectively.Grip strength,15 m walking time,blood calcium,WOMAC index change were statistically significant,treatment group(t =3.37,7.99,8.73,16.19,all P ＜ 0.05) and the control group(t =6.21,9.46,5.49,8.73,all P ＜ 0.05).Curative effect of two groups was not statistical significance(x2 =1.06,P＞ 0.05).Conclusions At present,use yunke combined with chondroitin sulfate or use yunke only,is all effective,safe and economical treatment method of KDB.It is worthy of clinical application.
